Seth T. Gammon, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
About Dr. Seth T. Gammon
About Dr. Gammon
Imaging, both aesthetic and scientific, stirs imaginations and inspires actions. When carefully and rigorously applied, imaging delivers data densely packed with quantitative and qualitative information. From super-resolution microscopy to “next-generation” sequencing and PET/MRI, imaging techniques and technologies form the foundation of cutting-edge clinical and preclinical research. Dr. Gammon’s goal is the development of novel radiopharmaceuticals and imaging inspired therapeutics.
Prior to his arrival at MD Anderson, Dr. Gammon worked on scientific problems in fluorescence correlation spectroscopy, bioluminescence spectral un-mixing, bioluminescence resonance energy transfer, and bioluminescence reporters for myeloperoxidase activity. This was followed by time in industry developing expertise and real world "know how" in product development and product management in the biotechnology and biomedical imaging space.
At MD Anderson, his research focuses on the invention and translation of imaging inspired therapeutics and deep tissue diagnostics. Major research areas of interest include: 1) Identifying high impact indications for PET imaging of respiratory burst imaging in patients and pre-clinical models based upon 18F-4FN co-invented by Dr. Gammon at MD Anderson. 2) Co-Inventing, developing and translating therapeutic antibodies including radiotherapeutics targeting 4Ig-B7H3 now licensed to RadioPharm Ventures. 3) Developing new imaging inspired therapeutics leveraging an iterative product development process right sized for academia.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Manager Optical Imaging Suite For CSI, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | Washington University, Saint Louis, Missouri, US, Chemical Biology, Ph.D |
| 2000 | University of Illinois, Champaign/Urbana, Champaign, Illinois, US, Major in Biophysics, Minor in Chemistry, BS |
Postgraduate Training
| 2007-2007 | Postgraduate Fellow, Chemical Biology, Washington University, St. Louis, MO |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2022
Post-doctoral Research Fellow, Washington University, St. Louis, MO, 2007 - 2007
Administrative Appointments/Responsibilities
Manager Optical Imaging Suite For CSI, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Other Professional Positions
Global In Vivo Product Manager, Carestream Health/Bruker, Woodbridge, CT, 2009 - 2013
Product Applications Specialist, Carestream Health, Woodbridge, CT, 2009 - 2009
Product Manager I, Sigma-Aldrich, St. Louis, MO, 2008 - 2009
Technical Marketing Specialist, Sigma-Aldrich, St. Louis, MO, 2007 - 2008
Institutional Committee Activities
Member, IACUC, 2021 - Present
Member, Faculty Senate, 2017 - 2022
Honors & Awards
| 2021 - 2022 | Elected Chair National IADP Group U24, NIH |
| 2020 - 2021 | Elected Co-Chair National IADP Group U24, NIH |
| 2018 | Poster Award in Metabolism EMIM 2018, EMIM |
| 2011 | North American Product Line Strategy of the Year Award in Preclinical Imaging Systems, Frost and Sullivan |
| 2007 | Ceil Degutis Memorial Award for Outstanding Achievement by a Graduate Student in Chemical Biology, Washington University School of Medicine |
| 2006 | Society for Molecular Imaging Student Travel, Society for Molecular Imaging (now WMIC) |
| 2002 | Nuclear Medicine Training Grant, NIH |
| 2001 - 2003 | Markey Pathway Fellowship, Washington University School of Medicine |
| 2000 | Phi Beta Kappa, Phi Beta Kappa Society |
| 1997 - 2000 | Campus Honors Program, University of Illinois |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Imaging Innate Immune Activation, Respiratory Burst at theIntersection of Metabolism and Function. Invited. Metabolism in Cancer 2023. Houston, Texas, US.
- 2019. PET Imaging of Innate Immune Response. Conference. PET Imaging of Innate Immune Response. Houston, TX, US.
- 2017. Mitochondrial OxPhos Inhibitor IACS-010759 and [18F] FAZA PET Imaging: Non-invasive Monitoring of Target Engagement. Conference. Mitochondrial OxPhos Inhibitor IACS-010759 and [18F] FAZA PET Imaging: Non-invasive Monitoring of Target Engagement. Houston, TX, US.
- 2015. FXR1 regulates Ras translation to drive oncogenic transformation with potential metabolic reprograming. Conference. FXR1 regulates Ras translation to drive oncogenic transformation with potential metabolic reprograming. Houston, TX, US.
- 2014. Zaprinast Inhibition of Glutaminase Activity is Toxic to Glutamine Addicted Pancreatic Tumor Cells. Conference. Zaprinast Inhibition of Glutaminase Activity is Toxic to Glutamine Addicted Pancreatic Tumor Cells. Houston, TX, US.
Regional Presentations
- 2023. PET Imaging of Innate Immune Response. Invited. Preclinical Imaging Symposium. Dallas, TX, US.
National Presentations
- 2024. Pairing Optical with Nuclear Imaging of RONS: Concept to Human. Invited. Frontiers in Biological Fluorescence 2024. Irvine, CA, US.
- 2022. An Online Repository for Pre-clinical Imaging Protocols (PIPs). Conference. NIH. Bethesda, MD, US.
- 2012. Cutting Edge Strategies and Technologies in Preclinical Imaging. Conference. Cutting Edge Strategies and Technologies in Preclinical Imaging. Miami, FL, US.
- 2002. Activity Relationships for Permeation Peptides Including Tat-Peptide Variants Using Radiotracer Methods. Conference. Activity Relationships for Permeation Peptides Including Tat-Peptide Variants Using Radiotracer Methods. Boston, MA, US.
International Presentations
- 2024. Translation of [18F]4FN: From Ideation to Proof of Concept in Humans. Invited. World Molecular Imaging Society 2024. Montreal, US.
- 2023. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed by Multi-modal Imaging. Conference. World Molecular Imaging Society 2023. Prague, US.
- 2010. Survey of Imaging Nanoparticles In Vivo, Their Efficacy and Lessons Learned”. Conference. Survey of Imaging Nanoparticles In Vivo, Their Efficacy and Lessons Learned”. Beijing, CN.
- 2009. Direction Injection Chemotherapy of a Synthetic Hydraphile Channel in Living Mice Monitored by Optical Imaging with a Near Infrared Fluorescent Probe. Conference. Direction Injection Chemotherapy of a Synthetic Hydraphile Channel in Living Mice Monitored by Optical Imaging with a Near Infrared Fluorescent Probe. Montreal, CA.
Formal Peers
- 2020. Use of optical & pre-clinical PET/CT imaging for developing a radiopharmaceutical that reports on respiratory burst. Invited, US.
- 2018. Utilizing a Pet Tracer to Non-Invasively Monitor the Pharmacodynamics of a New Anti-Cancer Drug. Invited. Nicosia, CY.
- 2016. Repetitive [18F]FAZA Imaging as a PD Marker of a Novel Inhibitor of Oxidative Phosphorylation. Invited. Houston, TX, US.
- 2016. Pre-clinical PET/CT - Powering Translational Research. Invited. Etlingen, DE.
- 2016. Career Panel. Invited. South Bend, IN, US.
- 2009. One perspective on careers away from the bench, and more importantly how to get there. Invited. St. Louis, MO, US.
- 2009. Advances in Molecular Imaging. Invited. Rio De Janeiro, BR.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Does Alzheimer’s Disease sensitize subjects to chemo-brain? |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP260266 |
| Date: | 2025 - 2027 |
| Title: | Novel Fc-Trimeric Fusion Proteins to Reverse Liver Fibrosis and Prevent HCC |
| Funding Source: | IGNITE |
| Role: | Co-PI |
| ID: | N/A |
| Date: | 2025 - 2028 |
| Title: | Does Alzheimer's disease sensitize subjects to chemo-brain? |
| Funding Source: | Department of Defense – Peer Reviewed Alzheimer’s Research Program Transforming Research Award |
| Role: | Co-I |
| ID: | AZ240284 |
| Date: | 2025 - 2027 |
| Title: | A Pilot Study to Correlate 4-[18F]fluoro-1-naphthol PET/CT Imaging with Chronic Graft Versus Host Disease Manifestations |
| Funding Source: | National Institutes of Health |
| Role: | Co-I |
| ID: | 1R21CA303350 |
| Date: | 2025 - 2026 |
| Title: | Biomarker Quantification of [18F]4FN for Radiation-Induced Arterial Injury |
| Funding Source: | MD Anderson – FY25 QIAC Partnership in Research Program Pilot Research Proposal Award |
| Role: | Co-PI |
| ID: | N/A |
| Date: | 2024 - 2029 |
| Title: | Molecular Imaging of Neutrophil Trap Driven Inflammation in Pancreatic Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2024 - 2026 |
| Title: | Study towards PET/CT Imaging of innate immune response to radiotherapy |
| Funding Source: | FY24 QIAC Partnership in Research Program Pilot Research Proposal Award |
| Role: | Co-PI |
| ID: | N/A |
| Date: | 2023 - 2024 |
| Title: | Fluorescent-Guided Surgery in Ovarian Cancer with a potentially Best-in-Class antibody MIL33B |
| Funding Source: | The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | Humanized hMIL33B-H3 Fc mutant (aka Betabart) targeting B7H3: Phase 1 clinical trial |
| Funding Source: | Radiopharm Ventures LLC |
| Role: | Co-I |
| Date: | 2023 - 2024 |
| Title: | Molecular Imaging of Innate Inflammation in Response to Statin-Mediated Inhibition of B7-H3 dimerization |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 CA277283-01 |
| Date: | 2023 - 2026 |
| Title: | PET Imaging of Immunotherapy-Induced Adverse Events |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230238 |
| Date: | 2022 - 2027 |
| Title: | Acquired Resistance to Therapy and Iron (ARTI) Center – Molecular Imaging Core |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U54CA274220 |
| Date: | 2022 - 2027 |
| Title: | [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA273130 |
| Date: | 2022 - 2024 |
| Title: | Exploring Statin-Mediated Changes of B7-H3 Dimerization in Glioblastoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center SPORE in Brain Cancer |
| Role: | Co-I |
| Date: | 2022 - 2023 |
| Title: | Improving Detection of Neurotoxicity in Immunotherapies QuickFire Challenge |
| Funding Source: | Johnson & Johnson |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2022 - 2027 |
| Title: | Understanding the Tumor Intrinsic and Extrinsic Roles of B7-H3 Expression in Gynecological Cancer Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | K99CA263040-01A1 |
| Date: | 2022 - 2026 |
| Title: | Molecular Imaging of Innate Inflammation in Response to Statin-Mediated Inhibition of B7-H3 dimerization |
| Funding Source: | MD Anderson Cancer Center - QIAC Partnership in Research Program |
| Role: | Co-PI |
| ID: | N/A |
| Date: | 2022 - 2024 |
| Title: | Making it work: From production of astatine-211 to animal studies, via fundamental chemistry |
| Funding Source: | Texas A&M University / Department of Energy |
| Role: | Co-I |
| Date: | 2022 - 2023 |
| Title: | Studying the Activation of Innate Immunity during Cytokine Release Syndrome |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | N/A |
| Date: | 2021 - 2026 |
| Title: | Unraveling dynamic co-evolutions of brain metastasis and the unique brain microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U54CA261702-01 |
| Date: | 2021 - 2025 |
| Title: | PET Imaging of ROS Burst in Immune Adverse Events: First-in-Human Evaluation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01AI165545 |
| Date: | 2021 - 2026 |
| Title: | An Academic-Industrial Partnership for Preclinical Cancer Studies with NIR-II Fluorescence Imaging: Instrumentation, Contrast Agents and Applications |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00011944 |
| Date: | 2021 - 2022 |
| Title: | Molecular Imaging for Interrogating Early Detection and Therapeutic Efficacy in Alzheimer’s Disease |
| Funding Source: | CP3 |
| Role: | Co-I |
| Date: | 2021 - 2026 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U54CA261702-01 |
| Date: | 2021 - 2023 |
| Title: | PET imaging of neuroinflammation with 4-[18F]fluoronaphthol |
| Funding Source: | QIAC |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | A novel PARP inhibitor PET tracer for breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA249329-01A1 |
| Date: | 2021 - 2023 |
| Title: | GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-19 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00011453 |
| Date: | 2020 - 2021 |
| Title: | Fluorescent-guided Surgery in Glioblastoma and Oligodendroglioma |
| Funding Source: | The University of Texas MD Anderson Cancer Center/NIH |
| Role: | Co-I |
| Date: | 2020 - 2025 |
| Title: | Multi-modal Imaging for the Prevention of Liver Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP200609 |
| Date: | 2020 - 2025 |
| Title: | Monitoring Therapeutic Intervention in Alcoholic Hepatitis by Multi-modal Imaging |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01AA028880-01 |
| Date: | 2020 - 2024 |
| Title: | A Novel PARP Inhibitor PET Tracer for Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC190368P1 |
| Date: | 2020 - 2025 |
| Title: | Breaking down tumor immune privilege through targeted hypoxia reduction |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA251816 |
| Date: | 2020 - 2022 |
| Title: | PET Imaging of Apoptosis and Inflammation for the Prevention of Hepatocellular Carcinoma (HCC) |
| Funding Source: | The University of Texas MD Anderson Cancer Center / Center for Advanced Biomedical Imaging |
| Role: | Co-PI |
| Date: | 2020 - 2025 |
| Title: | Diagnosis and Monitoring of Inflammation and Cell Death in NASH Using PET/CT |
| Funding Source: | NIH/NIDDK |
| Role: | Co-I |
| ID: | R01DK125518 |
| Date: | 2020 - 2025 |
| Title: | Targeting Oxidative Phosphorylation to Reduce the Incidence and Therapeutic Resistance of Melanoma Brain Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2020 - 2023 |
| Title: | A Novel PARP Inhibitor PET Tracer for Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA249329 |
| Date: | 2020 - 2025 |
| Title: | Targeted Inhibition of Autophagy for Treatment of Dormant Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA248195 |
| Date: | 2020 - 2022 |
| Title: | Multi-modal Imaging for the Prevention of Liver Cancer |
| Funding Source: | Emerson Collective |
| Role: | Collaborator |
| Date: | 2020 - 2024 |
| Title: | Imaging PARP1 activity using a novel PET tracer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP200375 |
| Date: | 2020 - 2023 |
| Title: | Reverting Tumor Hypoxia to Maximize Anti-tumor Immunity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP200236 |
| Date: | 2019 - 2021 |
| Title: | LC180427: Measuring Lung Tumor Acidosis with PET/MRI Contrast Agents |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Date: | 2019 - 2022 |
| Title: | Measuring Breast Tumor Acidosis with PET/MRI Contrast Agents |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC181478 |
| Date: | 2019 - 2023 |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Project 2 Co-Investigator |
| ID: | 2-P50-CA127001-11A1 |
| Date: | 2019 - 2020 |
| Title: | Flagship 3 Project 2: Early Phase Pharmacodynamic Window-of-opportunity Clinical Trial of IACS-010759 in Patients with Recurrent GBM |
| Funding Source: | The University of Texas MD Anderson Cancer Center - Glioblastoma Moonshot |
| Role: | Co-I |
| Date: | 2019 - 2023 |
| Title: | [18F]FAZA PET/CT for Monitoring Target Engagement of a Novel Complex I Inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R01-CA231506-01A |
| Date: | 2019 - 2024 |
| Title: | Integrative Imaging of Apoptosis in Tumors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA240520 |
| Date: | 2019 - 2020 |
| Title: | Measuring Tumor Acidosis with PET/MRI Contrast Agents |
| Funding Source: | NIH/NIBIB |
| Role: | Co-I |
| ID: | 1-R21-EB027197-01A1 |
| Date: | 2019 - 2023 |
| Title: | Imaging PARP1 Activity using a Novel PET Tracer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP190244 |
| Date: | 2019 - 2022 |
| Title: | [F-18]FAZA PET for Monitoring Targeted Mitochondrial Complex I Inhibition in Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP190270 |
| Date: | 2019 - 2022 |
| Title: | "Spin Batteries" for Imaging Biochemical Reactions in Cancer Systems In Vivo |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R21-CA236643-01 |
| Date: | 2018 - 2023 |
| Title: | Standardized Quantitative Imaging Biomarkers for Co-clinical Trials |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 1-U24-CA220280-01A1 |
| Date: | 2017 - 2022 |
| Title: | Standardized Quantitative Imaging Biomarkers for Co-Clinical Trials |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-U24-CA220280-01 |
| Date: | 2015 - 2018 |
| Title: | Metabolic Imaging of Patients with Prostate Cancer using Hyperpolarized Pyruvate |
| Funding Source: | The University of Texas MD Anderson Cancer Center Philanthropy |
| Role: | Co-I |
| Date: | 2015 - 2016 |
| Title: | Nerstian Probes as Vectors for Imaging and Therapeutic Modalities in Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2015 - 2016 |
| Title: | Nernstian Probes as Vehicles for Cell Impermeable Molecules of Interest in the Treatment and Diagnosis of Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP150643 |
| Date: | 2015 - 2015 |
| Title: | Employing Mouse Models to Translate Early Detection of Pancreas Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA195733-01 |
| Date: | 2015 - 2017 |
| Title: | Novel probes for near-infrared fluorescence imaging-guided oncologic surgery |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | EB020090 |
| Date: | 2013 - 2023 |
| Title: | Membrane Permeant Peptides for Imaging Cell Function |
| Funding Source: | NIH/NEI |
| Role: | Co-I |
| ID: | 2-R01-EY019587-18A1 |
| Title: | 2022-1029: Companion 18F-Fluoroazomycin Arabinoside ([18F]FAZA) PET/CT Imaging Trial for Treatment Assessment of Evofosfamide (TH-302) in Prostate, Pancreatic, and HPV(-) Head and Neck Tumors |
| Funding Source: | Immunogenesis |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Millward SW, Wei P, Piwnica-Worms D, Gammon ST. Can the Discovery of High-Impact Diagnostics Be Improved by Matching the Sampling Rate of Clinical Diagnostics to the Frequency Domain of Diagnostic Information?. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361314.
- Ayers GD, Cohen AS, Bae SW, Wen X, Pollard A, Sharma S, Claus T, Payne A, Geng L, Zhao P, Tantawy MN, Gammon ST, Manning HC. Reproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models. PLoS One 20(1):e0313123, 2025. e-Pub 2025. PMID: 39787098.
- Sutton MN, Glazer SE, Al Zaki A, Napoli A, Yang P, Bhosale P, Liu J, Gammon ST, Piwnica-Worms D. Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3. bioRxiv, 2024. e-Pub 2024. PMID: 39763965.
- Lavery TCM, Rasmussen CA, Katz AW, Kim CBY, Ver Hoeve JN, Miller PE, Sonnentag PJ, Christian BJ, Murphy CJ, Piwnica-Worms DR, Gammon ST, Qiu X, Kaufman PL, Nork TM. Development of Microcystoid Macular Degeneration in the Retina of Nonhuman Primates: Time-Course and Associated Pathologies. Curr Eye Res:1-8, 2024. e-Pub 2024. PMID: 39290166.
- Liu S, Gammon ST, Tan L, Gao Y, Kim K, Williamson IK, Pham J, Davidian A, Khanna R, Gould BD, Salazar R, Vitrac H, Dinh A, Lien EC, de L Vitorino FN, Gongora JM, Martinez SA, Lawrence CSC, Kransdorf EP, Leffer D, Hanson B, Garcia BA, Vander Heiden MG, Lorenzi PL, Taegtmeyer H, Piwnica-Worms D, Martin JF, Karlstaedt A. ATP-dependent citrate lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling of the Heart. bioRxiv, 2024. e-Pub 2024. PMID: 38948703.
- Sutton MN, Glazer SE, Muzzioli R, Yang P, Gammon ST, Piwnica-Worms D. Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling. Commun Biol 7(1):21, 2024. e-Pub 2024. PMID: 38182652.
- Liu A, Gammon ST, Pisaneschi F, Boda A, Ager CR, Piwnica-Worms D, Hong DS, Curran MA. Hypoxia-activated prodrug and anti-angiogenic therapy cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight 9(1), 2024. e-Pub 2023. PMID: 37988164.
- Qiu X, Gammon ST, Rasmussen C, Pisaneschi F, Kim CBY, Ver Hoeve J, Millward SW, Barnett EM, Nork TM, Kaufman PL, Piwnica-Worms D. In vivo scanning laser fundus and high-resolution OCT imaging of retinal ganglion cell injury in a non-human primate model with an activatable fluorescent-labeled TAT peptide probe. PLoS One 19(12):e0313579, 2024. e-Pub 2024. PMID: 39642160.
- Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568603.
- Radaram B, Glazer SE, Yang P, Li CW, Hung MC, Gammon ST, Alauddin M, Piwnica-Worms D. Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET. ACS Omega 8(19):17181-17194, 2023. e-Pub 2023. PMID: 37214681.
- Moore SM, Quirk JD, Lassiter AW, Laforest R, Ayers GD, Badea CT, Fedorov AY, Kinahan PE, Holbrook M, Larson PEZ, Sriram R, Chenevert TL, Malyarenko D, Kurhanewicz J, Houghton AM, Ross BD, Pickup S, Gee JC, Zhou R, Gammon ST, Manning HC, Roudi R, Daldrup-Link HE, Lewis MT, Rubin DL, Yankeelov TE, Shoghi KI. Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging. Tomography 9(3):995-1009, 2023. e-Pub 2023. PMID: 37218941.
- Gammon ST, Cohen AS, Lehnert AL, Sullivan DC, Malyarenko D, Manning HC, Hormuth DA, Daldrup-Link HE, An H, Quirk JD, Shoghi K, Pagel MD, Kinahan PE, Miyaoka RS, Houghton AM, Lewis MT, Larson P, Sriram R, Blocker SJ, Pickup S, Badea A, Badea CT, Yankeelov TE, Chenevert TL. An Online Repository for Pre-Clinical Imaging Protocols (PIPs). Tomography 9(2):750-758, 2023. e-Pub 2023. PMID: 37104131.
- Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, Shoghi KI, Quirk JD, Sriram R, Larson P, Lewis MT, Pautler RG, Kinahan PE, Muzi M, Chenevert TL. Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. Tomography 9(1):375-386, 2023. e-Pub 2023. PMID: 36828382.
- Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv 9(5):eadd6995, 2023. e-Pub 2023. PMID: 36724291.
- Liu TW, Gammon ST, Yang P, Ma W, Wang J, Piwnica-Worms D. Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma. J. Immunotherapy in Cancer, 2023. e-Pub 2023.
- Liu TW, Gammon ST, Yang P, Ma W, Wang J, Piwnica-Worms D. Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma. J Immunother Cancer 11(2), 2023. e-Pub 2023. PMID: 36805920.
- Gonzalez C, Williamson S, Gammon ST, Glazer S, Rhee JH, Piwnica-Worms D. TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Commun Biol 6(1):31, 2023. e-Pub 2023. PMID: 36635337.
- Gonzalez C, Williamson S, Gammon ST, Glazer S, Rhee JH, Piwnica-Worms D. TLR5 Agonists Enhance Anti-Tumor Immunity and Overcome Resistance to Immune Checkpoint Therapy. Communications Biology 6(1):31, 2023. e-Pub 2023.
- Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 610(7932):E15-E17, 2022. e-Pub 2022. PMID: 36198804.
- Pollard AC, de la Cerda J, Schuler FW, Kingsley CV, Gammon ST, Pagel MD. Evaluations of the performances of PET and MRI in a simultaneous PET/MRI instrument for pre-clinical imaging. EJNMMI Phys 9(1):70, 2022. e-Pub 2022. PMID: 36209262.
- Qiu X, Gammon ST, Johnson JR, Pisaneschi F, Millward SW, Barnett EM, Piwnica-Worms D. Apoptosis Detection in Retinal Ganglion Cells Using Quantitative Changes in Multichannel Fluorescence Colocalization. Biosensors (Basel) 12(9), 2022. e-Pub 2022. PMID: 36140078.
- Pisaneschi F, Gammon ST, Paolillo V, Qureshy SA, Piwnica-Worms D. Imaging of innate immunity activation in vivo with a redox-tuned PET reporter. Nat Biotechnol 4(6):965-973, 2022. e-Pub 2022. PMID: 35190688.
- Sutton MN, Gammon ST, Muzzioli R, Pisaneschi F, Radaram B, Yang P, Piwnica-Worms D. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Mol Imaging Biol 24(3):498-509, 2022. e-Pub 2022. PMID: 34905147.
- Salzillo TC, Mawoneke V, Weygand J, Shetty A, Gumin J, Zacharias NM, Gammon ST, Piwnica-Worms D, Fuller GN, Logothetis CJ, Lang FF, Bhattacharya PK. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells 10(10), 2021. e-Pub 2021. PMID: 34685601.
- Rao Y, Gammon ST, Sutton MN, Zacharias NM, Bhattacharya P, Piwnica-Worms D. Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner. J Biol Chem 297(1):100775, 2021. e-Pub 2021. PMID: 34022218.
- Liu TW, Gammon ST, Yang P, Fuentes D, Piwnica-Worms D. Myeloid cell-derived HOCl is a paracrine effector that trans-inhibits IKK/NF-κB in melanoma cells and limits early tumor progression. Sci Signal 14(677), 2021. e-Pub 2021. PMID: 33824181.
- Dann T, Raphel J, Gammon ST, Mastrovich Z, Van Avermaete T, Jeffrey J, Adusumilli S, Leevy WM. Anatase Titanium Dioxide Imparts Photoluminescent Properties to PA2200 Commercial 3D Printing Material to Generate Complex Optical Imaging Phantoms. Materials (Basel) 14(7), 2021. e-Pub 2021. PMID: 33917612.
- Liu TW, Gammon ST, Fuentes D, Piwnica-Worms D. Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor-Immune Interactions. Cells 10(3):1-19, 2021. e-Pub 2021. PMID: 33668735.
- Liu TW, Gammon ST, Piwnica-Worms D. Multi-Modal Multi-Spectral Intravital Microscopic Imaging of Signaling Dynamics in Real-Time during Tumor-ImmuneInteractions. Cells 10(3):1-28, 2021. e-Pub 2021. PMID: 33652682.
- Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
- Gammon ST, Engel BJ, Gores GJ, Cressman E, Piwnica-Worms D, Millward SW. Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death. Mol Imaging Biol 2(5):1310-1323, 2020. e-Pub 2020. PMID: 32519246.
- Rao Y, Gammon ST, Zacharais NM, Liu TW, Salzillo T, Xi Y, Wang J, Bhattacharya P, Piwnica-Worms D. Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactateconversion is rate-limited by monocarboxylatetransporter-1 in the plasma membrane. PNAS 117(36):22378-89, 2020. e-Pub 2020.
- Gammon ST, Liu TW, Piwnica-Worms D. Interrogating Cellular Communication in Cancer with Genetically Encoded Imaging Reporters. Radiology: Imaging Cancer 2(4):e190053, 2020. e-Pub 2020.
- Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
- Le Roux LG, Qiu X, Jacobsen MC, Pagel MD, Gammon ST, Piwnica-Worms DR, Schellingerhout D. Axonal Transport as an In Vivo Biomarker for Retinal Neuropathy. Cells 9(5), 2020. e-Pub 2020. PMID: 32456061.
- Dutta P, Pando SC, Mascaro M, Riquelme E, Zoltan M, Zacharias NM, Gammon ST, Piwnica-Worms D, Pagel MD, Sen S, Maitra A, Shams S, McAllister F, Bhattacharya PK. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. Int J Mol Sci 21(10), 2020. e-Pub 2020. PMID: 32466260.
- Vashisht Gopal YN, Gammon ST, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 25(21):6429-6442, 2019. e-Pub 2019. PMID: 31439581.
- Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells 8(12), 2019. e-Pub 2019. PMID: 31766580.
- Dutta P, Perez MR, Lee J, Kang Y, Pratt M, Salzillo TC, Weygand J, Zacharias NM, Gammon ST, Koay EJ, Kim M, McAllister F, Sen S, Maitra A, Piwnica-Worms D, Fleming JB, Bhattacharya PK. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. J Proteome Res 18(7):2826-2834, 2019. e-Pub 2019. PMID: 31120258.
- Biagiotti G, Pisaneschi F, Gammon ST, Machetti F, Ligi MC, Giambastiani G, Tuci G, Powell E, Piwnica-Worms H, Pranzini E, Paoli P, Cicchi S, Piwnica-Worms D. Multiwalled Carbon Nanotubes for Combination Therapy: a Biodistribution and Efficacy Pilot Study. J Mater Chem B 7(16):2678-2687, 2019. e-Pub 2019. PMID: 31073405.
- Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon ST, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol 21(1):86-94, 2019. e-Pub 2019. PMID: 29748904.
- Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar AM, Tong WP, Zhang S, Piwnica-Worms D, Bast RC, Millward SW. Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjug Chem 29(9):3180-3195, 2018. e-Pub 2018. PMID: 30168713.
- Fiacco SV, Kelderhouse LE, Hardy A, Peleg Y, Hu B, Ornelas A, Yang P, Gammon ST, Howell SM, Wang P, Takahashi TT, Millward SW, Roberts RW. Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications. Chembiochem 17(17):1643-51, 2016. e-Pub 2016. PMID: 27465925.
- Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523(7559):177-82, 2015. e-Pub 2015. PMID: 26106858.
- Qiu X, Johnson JR, Wilson BS, Gammon ST, Piwnica-Worms D, Barnett EM. Single-cell resolution imaging of retinal ganglion cell apoptosis in vivo using a cell-penetrating caspase-activatable peptide probe. PLoS One 9(2):e88855, 2014. e-Pub 2014. PMID: 24586415.
- Sasser TA, Van Avermaete AE, White A, Chapman S, Johnson JR, Van Avermaete T, Gammon ST, Leevy WM. Bacterial infection probes and imaging strategies in clinical nuclear medicine and preclinical molecular imaging. Curr Top Med Chem 13(4):479-87, 2013. e-Pub 2013. PMID: 23432010.
- Flentie K, Kocher B, Gammon ST, Novack DV, McKinney JS, Piwnica-Worms D. A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy. Cancer Discov 2(7):624-37, 2012. e-Pub 2012. PMID: 22728436.
- Özkaya H, Akcan AB, Aydemir G, Aydinöz S, Razia Y, Gammon ST, McKinney J. Salmonella typhimurium infections in BALB/c mice: a comparison of tissue bioluminescence, tissue cultures and mice clinical scores. New Microbiol 35(1):53-9, 2012. e-Pub 2012. PMID: 22378553.
- Sasser TA, Chapman SE, Li S, Hudson C, Orton SP, Diener JM, Gammon ST, Correcher C, Leevy WM. Segmentation and measurement of fat volumes in murine obesity models using X-ray computed tomography. J Vis Exp 4(62):e3680, 2012. e-Pub 2012. PMID: 22508524.
- Smith BA, Daschbach MM, Gammon ST, Xiao S, Chapman SE, Hudson C, Suckow M, Piwnica-Worms D, Gokel GW, Leevy WM. In vivo cell death mediated by synthetic ion channels. Chem Commun (Camb) 47(28):7977-9, 2011. e-Pub 2011. PMID: 21681307.
- Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott R, Suckow MA, Johnson JR, Piwnica-Worms D, Gokel GW, Smith BD, Leevy WM. In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc-dipicolylamine probe. Mol Pharm 8(2):583-90, 2011. e-Pub 2011. PMID: 21323375.
- Gross S, Gammon ST, Moss BL, Rauch D, Harding J, Heinecke JW, Ratner L, Piwnica-Worms D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 15(4):455-61, 2009. e-Pub 2009. PMID: 19305414.
- Gammon ST, Villalobos VM, Roshal M, Samrakandi M, Piwnica-Worms D. Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensors. Biotechnol Prog 25(2):559-69, 2009. e-Pub 2009. PMID: 19330851.
- Flentie KN, Qi M, Gammon ST, Razia Y, Lui F, Marpegan L, Manglik A, Piwnica-Worms D, McKinney JS. Stably integrated luxCDABE for assessment of Salmonella invasion kinetics. Mol Imaging 7(5):222-33, 2008. e-Pub 2008. PMID: 19123992.
- Leevy WM, Gammon ST, Johnson JR, Lampkins AJ, Jiang H, Marquez M, Piwnica-Worms D, Suckow MA, Smith BD. Noninvasive optical imaging of staphylococcus aureus bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity group conjugated to a near-infrared fluorophore. Bioconjug Chem 19(3):686-92, 2008. e-Pub 2008. PMID: 18260609.
- Moss BL, Gross S, Gammon ST, Vinjamoori A, Piwnica-Worms D. Identification of a ligand-induced transient refractory period in nuclear factor-kappaB signaling. J Biol Chem 283(13):8687-98, 2008. e-Pub 2008. PMID: 18203717.
- Gammon ST, Bernstein M, Schuster DP, Piwnica-Worms D. A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation. Anal Biochem 369(1):80-6, 2007. e-Pub 2007. PMID: 17658449.
- Bullok KE, Maxwell D, Kesarwala AH, Gammon S, Prior JL, Snow M, Stanley S, Piwnica-Worms D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 46(13):4055-65, 2007. e-Pub 2007. PMID: 17348687.
- Johnson JR, Fu N, Arunkumar E, Leevy WM, Gammon ST, Piwnica-Worms D, Smith BD. Squaraine rotaxanes: superior substitutes for Cy-5 in molecular probes for near-infrared fluorescence cell imaging. Angew Chem Int Ed Engl 46(29):5528-31, 2007. e-Pub 2007. PMID: 17585399.
- Leevy WM, Gammon ST, Jiang H, Johnson JR, Maxwell DJ, Jackson EN, Marquez M, Piwnica-Worms D, Smith BD. Optical imaging of bacterial infection in living mice using a fluorescent near-infrared molecular probe. J Am Chem Soc 128(51):16476-7, 2006. e-Pub 2006. PMID: 17177377.
- Ippolito JE, Merritt ME, Bäckhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI. Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc Natl Acad Sci U S A 103(33):12505-10, 2006. e-Pub 2006. PMID: 16895983.
- Gammon ST, Leevy WM, Gross S, Gokel GW, Piwnica-Worms D. Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. Anal Chem 78(5):1520-7, 2006. e-Pub 2006. PMID: 16503603.
- Leevy WM, Gammon ST, Levchenko T, Daranciang DD, Murillo O, Torchilin V, Piwnica-Worms D, Huettner JE, Gokel GW. Structure-activity relationships, kinetics, selectivity, and mechanistic studies of synthetic hydraphile channels in bacterial and mammalian cells. Org Biomol Chem 3(19):3544-50, 2005. e-Pub 2005. PMID: 16172693.
- Barcellona ML, Gammon ST, Hazlett T, Digman MA, Gratton E. Polarized fluorescence correlation spectroscopy of DNA-DAPI complexes. Microsc Res Tech 65(4-5):205-17, 2004. e-Pub 2004. PMID: 15630690.
- Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 101(33):12288-93, 2004. e-Pub 2004. PMID: 15284440.
- Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D. Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake. Bioconjug Chem 14(2):368-76, 2003. e-Pub 2003. PMID: 12643747.
Invited Articles
- Gross S, Gammon ST, Moss B, Piwnica-Worms, D. Real-Time Bioluminescence Imaging of Myeloperoxidase Activity in Small Laboratory Animals. Nature Protocols, 2009. e-Pub 2009.
Review Articles
- Karlstaedt A, Barrett M, Hu R, Gammons ST, Ky B. Cardio-Oncology: Understanding the Intersections Between Cardiac Metabolism and Cancer Biology. JACC Basic Transl Sci 6(8):705-718, 2021. e-Pub 2021. PMID: 34466757.
- Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaipparettu BA, McAllister F, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya PK. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells 8(4), 2019. e-Pub 2019. PMID: 30978984.
- Gammon ST, Foje N, Brewer EM, Owers E, Downs CA, Budde MD, Leevy WM, Helms MN. Preclinical anatomical, molecular, and functional imaging of the lung with multiple modalities. Am J Physiol Lung Cell Mol Physiol 306(10):L897-L914, 2014. e-Pub 2014. PMID: 24658139.
- Bullok KE, Gammon ST, Violini S, Prantner AM, Villalobos VM, Sharma V, Piwnica-Worms D. Permeation peptide conjugates for in vivo molecular imaging applications. Mol Imaging 5(1):1-15, 2006. e-Pub 2006. PMID: 16779965.
Abstracts
- Muzzioli R, Pisaneschi P, Gammon ST, Piwnica-Worms, D. [18F]Talazoparib: a novel potential PET imaging agent of PARP. Nuclear Medicine and Biology #O-10(S7-S8):96-97, 2021. e-Pub 2021.
- Muzzioli R, Pisaneschi P, Gammon ST, Piwnica-Worms, D. ENBPI ligand for 68 Ga: synthesis, radiolabeling optimization, and pilot myocardial perfusion imaging with ECG-gated PET. Nuclear Medicine and Biology #SP-041(S57):96-97, 2021. e-Pub 2021.
- Muzzioli R, Pisaneschi P, Gammon, ST, Piwnica-Worms, D. [18F]Talazoparib: a novel potential PET imaging agent of PARP. Nuclear Medicine and Biology 96-97:S7-S8, 2021. e-Pub 2021.
- Muzzioli R, Pisaneschi P, Gammon, ST, Piwnica-Worms, D. ENBPI ligand for 68 Ga: synthesis, radiolabeling optimization, and pilot myocardial perfusion imaging with ECG-gated PET. Nuclear Medicine and Biology 96-97:S57, 2021. e-Pub 2021.
- Pollard AC, Kotrotsou A, Cerda DL, J, Schuler FW, Pisaneschi F, Gammon ST, Pagel MD. PET/MRI contrast agents for measuring tumor extracellular pH. European Molecular Imaging Meeting, 2020. e-Pub 2020.
- Pollard AC, Kotrotsou A, de la Cerda J, Schuler FW, Pisaneschi F, Gammon ST, Pagel MD. A PET/MRI contrast agent for measuring tumor extracellular pH. the International Society for Magnetic Resonance in Medicine Meeting, 2020. e-Pub 2020.
- Pollard AC, Kotrotsou A, Cerda DL, J, Schuler FW, Pisaneschi F, Gammon ST, Pagel MD. A PET/MRI contrast agent for measuring tumor extracellular pH. The International Society for Magnetic Resonance in Medicine Meeting, 2020. e-Pub 2020.
- Gammon ST, Pisaneschi F, Piwnica-Worms D. A novel radio-pharmaceutical to image activation of the innate immune system in vivo. The Journal of Immunology, 2020. e-Pub 2020.
- Pisaneschi F, Engel B, Uddin MN, Gammon ST, Fiacco S, Piwnica-Worms D, Millward S. Click chemistry on TracerLab: Towards GMP manufacturing of high molar activity F-18 PET tracers. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019. e-Pub 2019.
- Liu, TW, Gammon, ST, Piwnica-Worms, D. Innate immune cells expressing myeloperoxidase directly inhibit tumor NF-kappa B transcriptional activation during tumor initiation. CANCER RESEARCH, 2018. e-Pub 2018.
- Glazer S, Gammon ST, Piwnica-Worms D. B7-H3 regulates NF-kB signaling in cancer cells by modulating the degradation and re-synthesis of IkBα. CANCER RESEARCH, 2018. e-Pub 2018.
- Rao Y, Gammon ST, Piwnica-Worms D. Differential metabolic targeting of PDAC cells with Zaprinast. Cancer Research, 2018. e-Pub 2018.
- Pisaneschi F, Gammon ST, Bandi ML, Smith M, Davies MA, Nanda VG, Di Francesco ME, Marszalek J, Piwnica-Worms D. Mitochondrial OxPhos Inhibitor IACS-010759 and [18F]FAZA PET Imaging: Non-invasive Monitoring of Target Engagement. WMIC 2016 - New York, 2016. e-Pub 2016.
- Kelderhouse L, Hardy A, Pisaneschi F, Peleg Y, Hu B, Ornelas A, Yang P, Gammon S, Shannon H, Piwnica-Worms D, Wang P, Takahashi T, Roberts R, Fiacco S, Millward S. Directed evolution of PET imaging agents by scanning unnatural protease resistance (SUPR) mRNA display. Amercian Chemical Society, 2016. e-Pub 2016.
- Kelderhouse LE, Hardy A, Pisaneschi F, Gray JP, Gammon S, Roberts RW, Takahashi TT, Fiacco S, Millward SW. SUPR-PET: Nuclear imaging of Her2-positieve breast cancer with SUPR peptides. CANCER RESEARCH, 2016. e-Pub 2016.
- Lin YH, Millward S, Gammon ST, Satani N, Hammoudi N, Gray JP, Kelderhouse LE, Schroeder H, Muller F. Rhodamine esters as fluorescent tumor painting agents for glioblastoma. Cancer Research, 2016. e-Pub 2016.
- Kelderhouse L, Hardy A, Takahashi TT, Gammon S, Howell S, Yang P, Wang P, Roberts RW, Fiacco S, Millward SW. SUPR peptides as novel targeted molecular imaging agents for Her2. CANCER RESEARCH, 2015. e-Pub 2015.
- Rao Y, Elhammali A, Gammon ST, Piwnica-Worms D. Zaprinast inhibits glutaminase and growth of glutamine-addicted cells. JOURNAL OF NUCLEAR MEDICINE, 2015. e-Pub 2015.
- Flentie K, Gammon ST McKinney JS, Piwnica-Worms D. Salmonella Interactions with Neoplastic Cells. Abstracts of the General Meeting of the American Society for Microbiology, 2010. e-Pub 2010.
Book Chapters
- Salzillo TC, Hu J, Nguyen L, Whiting N, Lee J, Weygand J, Dutta P, Pudakalakatti S, Millward NZ, Gammon ST, Lang FF, Heimberger AB, Bhattacharya PK. Interrogating Metabolism in Brain Cancer. In: Magn Reson Imaging Clin N Am. 4, 687-703, 2016.
- Sivapackiam J, Gammon ST, Harpstrite SE, Sharma V. Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases. In: Methods Mol Biol, 141-81, 2010.
Books (edited and written)
- Gammon ST, Samuel B. SACademic Guide. Washington University Press, 2003.
Patents
- Sharma V, Gammon S, Piwnica-Worms D, Submitted GS. Bioluminescence Imaging of Myeloperoxidase Activity In Vivo: Methods, Composition, and Apparatus Therefore. Patent Number: 13/127,448.
Patient Reviews
CV information above last modified July 21, 2025